Results
Filtros
Regulation of cultivation comes up for discussion at Anvisa after request for extension
10/06/2025The subject is on the agenda of the 6th Public Meeting of the Collegiate Board of Directors (Dicol) of 2025, scheduled for Wednesday (10/08)
Anvisa warns of deadline for comments on agenda including review of RDC 327/2019
Submission of registrations, videos, and requests for confidentiality ends at 11:59 pm this Friday (5); item revising rules for cannabis products will be defined at the Dicol meeting on December 10
Anvisa Collegiate Board has new composition defined after director's departure
Marcelo Mario Matos Moreira takes over as substitute in the Fourth Board, filling the vacancy of the former rapporteur of the review of RDC 327
Proposal to regulate cannabis cultivation is taken off Anvisa's meeting agenda
Decision postpones vote on new rules for cultivating low-THC varieties; new date for analysis not yet defined
Anvisa may vote on rules for national cultivation and control of cannabis this Wednesday (13)
Change may authorize cultivation by companies under strict control, with a limit of 0.3% THC; measure complies with a decision from the Superior Court of Justice (STJ) related to cultivation regulation.
Proposal to restrict Cannabis importation (RDC 660) sparks reaction in the market
Proposal in the review of RDC 327/2019 to RDC 660/2022 divides opinions and raises doubts about access and judicialization
Anvisa suspends review of RDC 327 after director's request for further analysis
Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence
Anvisa may vote on maintaining or removing the agenda item for the review of RDC 327/2019, which regulates medicinal cannabis products
The item revising RDC 327/2019 reaches a decisive week at Anvisa, and the sector awaits to know if the topic will proceed to a vote or be postponed once again
Cannabidiol grows over 70% in the pharmacy channel; Anvisa's RDC 327 review generates optimism in the sector
According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence
“Extended deadline creates the possibility of presenting a more consistent proposal,” says Anvisa director about regulation of cultivation
Thiago Campos advocates for the extension of the regulation deadline and reinforces the importance of social listening in the process
Public participation in Anvisa's regulatory agenda continues until September 15
Public consultation allows society to give opinions on the agency's priorities for the next two years; preliminary list does not include cannabis
RDC 327 review rapporteur bids farewell to Anvisa this Friday (19).
Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027
CFF advocates for magistral manipulation amid changes in Cannabis regulation
Entity reinforces that personalized preparations are essential when industrialized products do not meet clinical needs
CRF-SP warns of risk of setback and legal uncertainty in the review of the Cannabis regulation
According to Marcelo Polacow Bisson, excluding pharmacies' manipulation leads to lack of assistance; Anvisa's proposed text on the Cannabis regulation is also criticized for bypassing procedural rites
Anvisa Regulatory Agenda 2026 - 2027 opens space for society suggestions, including on cannabis
Population and regulated sectors have the opportunity to indicate topics of interest for the next biennium
Countdown: government has until September 30th to publish regulation on cannabis cultivation
Deadline set by STJ puts pressure on ministries and Anvisa to conclude pending stages of the action plan
Associations may have more space in the debate on the regulation of cannabis cultivation in Brazil
Entrepreneur Fabrício Penafiel considers the inclusion of practical experience of producers in the proposal, with a deadline set for September 30th, a historic opportunity.
RDC 327 vote postponed at Anvisa; ABIQUIFI evaluates new deadline as "legitimate tool"
Brazilian Association of Pharmaceutical Inputs Industry trusts that director Thiago Campos' request for review will result in a more thorough analysis, maintaining the expectation of regulatory framework completion in January 2026
Anvisa to decide today the future of RDC 327 in a meeting that could redefine rules for cannabis products in Brazil
Norm that regulates manufacturing, importation, prescription, and inspection may be entirely revoked and replaced by a new regulatory framework; decision will be made at the Collegiate Board meeting.
Anvisa suspends review of RDC 327 after director's request for further analysis
Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence